Clinical Trial Update: Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating ibrutinib as maintenance therapy in elderly patients with central nervous system lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Rabin Medical Center | Conditions: Central Nervous System Lymphoma | Phase 2 | Status: UNKNOWN